Form 8-K - Current report:
SEC Accession No. 0001493152-25-005043
Filing Date
2025-02-05
Accepted
2025-02-05 17:02:43
Documents
24
Period of Report
2025-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57744
2 ex4-1.htm EX-4.1 143476
3 ex5-1.htm EX-5.1 16014
4 ex10-1.htm EX-10.1 541727
5 ex99-1.htm EX-99.1 14431
6 ex99-2.htm EX-99.2 14334
7 ex99-3.htm EX-99.3 13856
8 ex5-1_001.jpg GRAPHIC 8766
9 ex5-1_002.jpg GRAPHIC 10124
10 ex5-1_003.jpg GRAPHIC 9143
11 ex99-3_001.jpg GRAPHIC 14208
  Complete submission text file 0001493152-25-005043.txt   1251169

Data Files

Seq Description Document Type Size
12 XBRL SCHEMA FILE bctx-20250203.xsd EX-101.SCH 3750
13 XBRL DEFINITION FILE bctx-20250203_def.xml EX-101.DEF 29998
14 XBRL LABEL FILE bctx-20250203_lab.xml EX-101.LAB 36631
15 XBRL PRESENTATION FILE bctx-20250203_pre.xml EX-101.PRE 27021
27 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5668
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 25594217
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)